Switzerland

F. Hoffmann-La Roche

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Roche Actemra studies against COVID-19 could be done this month

Lead Product(s): Tocilizumab

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 06, 2020

Details:

Phase III clinical trial is evaluating the safety and efficacy of tocilizumab plus standard of care in hospitalised adult patients with severe COVID-19 pneumonia, vs placebo and standard of care.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Novartis, Incyte will Test Jakafi in 2nd COVID-19 Study

Lead Product(s): Ruxolitinib

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 05, 2020

Details:

Incyte has initiated a Phase 3 clinical trial to evaluate the efficacy and safety of ruxolitinib plus standard-of-care, compared to SoC therapy alone, in COVID-19 associated cytokine storm.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Novartis Plans COVID-19 Testing for Ilaris

Lead Product(s): Canakinumab

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 28, 2020

Details:

The CAN-COVID trial will examine the efficacy of utilizing canakinumab, to treat a type of severe immune overreaction called cytokine release syndrome in people with COVID-19 pneumonia.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

F. Hoffmann-La Roche

Roche Actemra studies against COVID-19 could be done this month

Novartis Pharmaceuticals Corporation

Novartis, Incyte will Test Jakafi in 2nd COVID-19 Study

Novartis Pharmaceuticals Corporation

Novartis Plans COVID-19 Testing for Ilaris